Skip to content
lifestyle.tvshowauditions.info
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Nasus Pharma, Ltd.
Nasus Pharma Announces Positive Results from Preclinical Pharmacokinetic and Safety Study of Intranasal Ondansetron (NS003)
June 9, 2026
Nasus Pharma to Host Virtual KOL Event on June 10, 2026 to Discuss NS002 for the Treatment of Anaphylaxis
June 1, 2026
Nasus Pharma to Participate in Upcoming Investor Conferences
May 1, 2026
Nasus Pharma Advances NS002 Towards Pivotal Study Following Positive Phase 2; Reports Annual Results and Provides Business Update
March 25, 2026
Nasus Pharma Announces Positive Top Line Data from Phase 2 Clinical Study of NS002: Achieves Significantly Superior and Faster Epinephrine Delivery Compared to EpiPen® with Accelerated Speed to Therapeutic Threshold
March 16, 2026
Nasus Pharma to Present Topline Analysis from NS002 Intranasal Epinephrine Powder Phase 2 Single and Repeat Dose Clinical Study
March 9, 2026
Nasus Pharma to Present and Participate in the Upcoming Life Sciences Investor Forum
March 9, 2026
Nasus Pharma to Participate in Upcoming Investor Conferences
February 24, 2026
Nasus Pharma to Present Data Highlighting Superior Nasal Deposition and Stability of Intranasal Epinephrine Powder at AAAAI 2026
February 17, 2026
Nasus Pharma Announces Closing of $15.0 Million Private Placement
February 13, 2026
1
2
Next Page
→